Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 6,448 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Kidney Clear all

Conditions: Fabry Disease
Interventions: DRX005B; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Kidney Stone, Nephrolithiasis
Interventions: Ureteroscopy, Percutaneous Nephrolithotomy, Shock Wave Lithotripsy; Procedure
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 8 Years to 21 Years
Enrollment: 1,290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 24 more

Conditions: Immunologic Diseases, Autoimmune Diseases, Systemic Lupus Erythematosus, Lupus Nephritis, Lupus Glomerulonephritis
Interventions: Abetimus sodium (LJP 394); Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 66
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 48 more

Conditions: Hepatitis C, Cirrhosis
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland • Falls Church, Virginia

Conditions: Work Related Stress
Interventions: Somatic Psychoeducational Intervention; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Polycystic Kidney Disease
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: End Stage Renal Disease (ESRD), Kidney Disease
Interventions: Performance Feedback Reports on Referral and Evaluation Closures, Dialysis Facility Awareness Campaign, Patient Contact via Preferred Method, Phone Call to Dialysis Facility During the Patient's Dialysis Session, Phone Call to Provider, Transplant Referral Communication Platforms or Email to Communicate Patient Status and No-Show, Audit and Tracking of Patient Contact Attempts Prior to Referral Closure; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Durham, North Carolina + 1 more

Conditions: Lowe Syndrome
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Hydroxychloroquine, IL-2; Drug
Lead sponsor: Leonard Appleman; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 7
States / cities: Maywood, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 4 more

Conditions: Metastatic Renal Cell Cancer
Interventions: RX-0201; Drug
Lead sponsor: Rexahn Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 7
States / cities: Tucson, Arizona • Duarte, California • Albuquerque, New Mexico + 4 more

Conditions: Anemia
Interventions: Peginesatide; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 7 more

Conditions: Atypical Hemolytic Uremic Syndrome
Interventions: Eculizumab; Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: Ureteral Calculus, Ureterolithiasis, Ureteral Stone
Interventions: Silodosin, Tamsulosin; Drug
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: End Stage Renal Disease, Kidney Failure
Interventions: Provider educational materials, Patient letters; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: New York, New York • Cleveland, Ohio

Conditions: End Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Kidney Disease
Interventions: Moda-flx Hemodialysis System; Device
Lead sponsor: Diality Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Ontario, California

Conditions: HIV Infections, Fanconi Syndrome, Kidney Disease, Renal Impairment
Interventions: Blood Draws; Procedure
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 10
States / cities: Los Angeles, California • Denver, Colorado • Miami, Florida + 7 more

Conditions: Renal Impairment, Healthy Volunteer
Interventions: Entinostat; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Knoxville, Tennessee

Conditions: Anemia, Renal Insufficiency, Chronic, Renal Anemia
Interventions: Daprodustat; Drug
Lead sponsor: USRC Kidney Research; Network
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lone Tree, Colorado

Conditions: Kidney Disease
Interventions: Low Salt Diet, Usual Salt Diet; Dietary Supplement
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 85 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Urinary Calculi, Urinary Stones, Urinary Tract Stones
Interventions: OMS201, Vehicle; Drug
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Orange, California • Dallas, Texas

Conditions: Nephrotic Syndrome, Lipodystrophy, Metabolic Syndrome, Healthy Volunteer, Diabetes, Metabolic Associated Steatotic Liver Disease
Interventions: High carb then high fat breakfast, High fat then high carb breakfast; Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Renal Cell Cancer
Interventions: Axitinib; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 4
States / cities: Duarte, California • Cleveland, Ohio • Columbus, Ohio + 1 more

Conditions: Chronic Kidney Failure, HIV Infection
Interventions: immunosuppressive regimen designed to complement HAART; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heart Failure, Congestive
Interventions: Relaxin, Placebo; Drug
Lead sponsor: Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies; Industry
Eligibility: 18 Years and older
Enrollment: 1,161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois • Detroit, Michigan

Search by objective public record fields.

Alpha-Galactosidase A Replacement Therapy for Fabry Disease

Pediatric KIDney Stone (PKIDS) Care Improvement Network

Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease

Transplant-Related Accelerated Progression of Hepatitis C

Potential Benefits of the Somatic Psychoeducational Intervention

Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease

RaDIANT Health Systems Intervention

Genetic Analysis of Oculocerebrorenal Syndrome of Lowe

Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer

Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.

Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment

Silodosin Versus Tamsulosin for Treatment of Ureteral Stones

Using Shared Decision Making to Improve Kidney Transplantation Rates

First Evaluation of the Moda-Flx Hemodialysis System™ in Real World Clinical Settings

Fanconi Syndrome Due to ARVs in HIV-Infected Persons

A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function

A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease

Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial

Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urinary Tract-Located Stones

Effects of Meal Macronutrients on Postprandial Lipids

Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer

Kidney Transplant for HIV-Infected Patients in Renal Failure

Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure